Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYN002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Danish Growth Fund
Deal Size : $31.8 million
Deal Type : Series A Financing
Details : Synklino will advance its drug candidate SYN002 for the treatment of Cytomegalovirus (CMV), into both ex vivo and in vivo Phase 1 clinical trials and generate safety and efficacy data establishing a solid foundation.
Product Name : SYN002
Product Type : Protein
Upfront Cash : Undisclosed
August 06, 2022
Lead Product(s) : SYN002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Danish Growth Fund
Deal Size : $31.8 million
Deal Type : Series A Financing